Ranbaxy Receives US FDA Approval For Ramipril Capsules

Ranbaxy Laboratories announced that the company received US FDA approval for its abbreviated new drug application to market and manufacture Ramipril capsules of 5 mg and 10 mg strengths.

Ramipril is indicated in patients of 55 years or older, who are at high risk of developing a major cardiovascular event or diabetes that is accompanied by at least one other cardiovascular risk factor to reduce the risk of myocardial infarction, stroke or death from cardiovascular causes.

For comments and feedback contact: editorial@rttnews.com

Follow RTT